NICE has requested further information from the company, EUSA Pharma, before the committee can make a decision on this technology and we have been working with the company on this data request. The company are not in a position to provide this information in time for it to be considered at the meeting we provisionally scheduled in February 2018.
As a result, the discussion of this topic has been taken off the February agenda. We are working on re-scheduling this discussion, and will update you as soon as we have more information.